SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com.
Power-One, Inc. (Nasdaq: PWER) $11.15. Today announced the launch of its PVI-250 and PVI-300 Central PV inverters for the North American marketplace. Power-One is now the second largest global PV inverter manufacturer with over 800 MW of installed PV inverters in the first half of 2010.
The launch of these inverters highlights Power-One's expanding family of best-in-class inverters for the North American solar market. The inverters, which are UL certified to meet NEMA 3R outdoor specifications, will be available in 250kW and 300kW outdoor variations and listed for use in the United States and Canada.
What They Do: Power-One designs and manufactures energy-efficient power conversion and power management solutions, including inverters for alternative/renewable energy (solar and wind) and products for routers, data storage and servers, wireless communications, optical networking, semiconductor test equipment, industrial markets and custom applications.
Somaxon Pharmaceuticals (Nasdaq: SOMX) $3.83. Today announced that Silenor (doxepin) now is commercially available by prescription in the United States. Somaxon has implemented a wholesale and retail stocking program to disseminate Silenor 3 mg and 6 mg dosepacks to pharmacies across the United States. Silenor is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.
“The commercial availability of Silenor, the first and only prescription product approved for the treatment of sleep maintenance insomnia that is not a controlled substance, is an important milestone for Somaxon and marks the completion of our product launch preparations,” said Richard W. Pascoe, Somaxon’s President and Chief Executive Officer. “We look forward to promoting this highly differentiated product to healthcare providers alongside our co-promotion partner, Procter & Gamble. Our combined sales teams will begin full-scale, field-based promotion of the product on September 20, 2010, targeting approximately 35,000 physicians and 25,000 pharmacies across the U.S.”
What They Do: Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.
DryShips Inc. (Nasdaq: DRYS) $4.42. Today announced that it has obtained an additional waiver letter under its $230 million loan facilities up to December 1, 2010. The previous waiver letter expired on August 15, 2010. Furthermore, the Company announced the signing of two supplemental (waiver) agreements with Piraeus Bank, which among other things, extend the waivers under the $130 million loan facility dated March 31, 2008, as amended and the $90 million loan facility dated October 5, 2007, as amended, up to March 31, 2012.
What They Do: DryShips is an owner and operator of drybulk carriers and offshore oil deep water drilling that operate worldwide.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com.
